Beyond the Rift: The Future of Pharmacy and the Pharmaceutical Industry

REFERENCES

• Bezold C, ed. Pharmaceuticals in the year 2000—The changing context for drug R&D. Alexandria, VA: Institute for Alternative Futures; 1983.
   Google Scholar
• Bezold C, et al. Pharmacy in the 21st century: Planning for an uncertain future. NP: Institute for Alternative Futures and Project Hope; 1985.
   Google Scholar
• Symposium for pharmacy association executives—Future scenario workshop. Captiva Island, November 1993. Report available from Institute for Alternative Fu-tures.
   Google Scholar
• Reality & vision: Bridging the gap. Conference at Litchfield Park, Arizona, No-vember 2004. Sponsored by Zeneca Pharmaceuticals.
   Google Scholar
• Milbauer A, Baker W. Charting pharmacy's future. Am Druggist. 1995; (Apr):33.
   Google Scholar
• Salk J. The survival of the wisest. Harper & Row; 1973.
   Google Scholar
• Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington, DC: National Academies Press; 2001.
   Google Scholar
• US Department of Health and Human Services. Centers for Disease Control and Prevention. Division of Nutrition and Physical Activity. Overweight and obesity. www.cdc.gov/nccdphp/dnpa/obesity/ (accessed 2007 Jul 5).
   Google Scholar
• Institute for Alternative Futures and Yale School of Public Health. The diabetes epidemic: The case for changing diabetes. November 2005. www.altfutures.com/fore- sight/Yale%20Diabetes%20Crisis%20Report%20Nov%202005.pdf (accessed 2007 Jul 5).
   Google Scholar
• US Department of Health and Human Services. Centers for Disease Control and Prevention. The burden of chronic diseases and their risk factors: National and state perspectives 2004. www.cdc.gov/nccdphp/burdenbook2004/preface.htm (accessed 2007 Jul 5).
   Google Scholar
• IMS Health. IIVIS world review. 2003.
   Google Scholar
• Culliton BJ. Extracting knowledge from science: A conversation with Elias Zerhouni. Health Aff 2006; 25(3):w94–w103 [Web exclusive]. doi: 10.1377/ hlthaff.25.w94.
   Google Scholar
• Institute for Alternative Futures. The 2029 Project: Achieving an ethical future for biomedical R&D. www.altfutures.com/2029.asp (accessed 2007 Jul 5).
   Google Scholar
• See, for example: IBM Business Consulting Services. Pharma 2010: The threshold of innovation. February 2006. www-935.ibm.com/services/us/index.wss/ ibvstudy/imc/a1001099?pf = y&cntxt = a1001099 (accessed 2007 Jul 5).
   Google Scholar
• Institute for Alternative Futures. The Biomonitoring Futures Project: Final re-port & recommendations. November 2006. www.altfutures.com/BFWBFP_Final_Re-port_10-27.pdf (accessed 2007 Jul 5).
   Google Scholar
• Gottleib S. Speech before the 2006 Conference on Adaptive Trial Design. 2006 Jul 10. www.fda.gov/oc/speeches/2006/trialdesign0710.html (accessed 2007 Jul 5).
   Google Scholar
• Institute for Alternative Futures. Clinical development 2005. 1997. www. altfutures.com/pubs/ClinicalDevReport.pdf (accessed 2007 Jul 5).
   Google Scholar
• North Carolina Association of Pharmacists. The Asheville Project. www. nepharmacists.org/displaycommon.cfm?an = l&subarticlenbr = 41 (accessed 2007 Jul 5).
   Google Scholar
• American Pharmacists Association Foundation. Diabetes Ten City Challenge. www.aphafoundation.org/programs/Diabetes_Ten_City_Challenge/ (accessed 2007 Jul 5).
   Google Scholar
• Institute for Alternative Futures. The looming diabetes crisis: Can it be pre-vented? Foresight Seminar Meeting, June 23, 2006, Washington, DC. www. altfutures.com/foresight/Summary_Foresight_Final.doc.pdf (accessed 2007 Jul 5).
   Google Scholar
• Ehman RL, Hendee WR, Welch MJ, et al. Blueprint for imaging in biomedical research. Radiology. 2007; 244:12–27. radiologyssnajnls.org/cgi/content/ful1/244/1/ 12 (accessed 2007 Jul 5).
   PubMedGoogle Scholar
• Wagner EH. The role of patient care teams in chronic disease management. BMJ. 2000; 320:569-72. www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 1117605 (accessed 2006 Aug 15).
   Google Scholar
• An example of these combinations of targeted therapeutics and diagnostics is the use of the diagnostic test for the HER-2/neu gene for breast cancers susceptible to Herceptin®.
   Google Scholar
• To see a list of companies supporting VistA and read a range of white papers on VistA and open-source software in health care, visit the VistA Software Alliance at www.vistasoftware.org/resources/index.html (accessed 2007 Jul 5).
   Google Scholar
• You can visit the different PLoS journals at www.plos.org (accessed 2007 Jul 5).
   Google Scholar
• Mathews AW. Reading fine print, insurers question studies of drugs. Wall Street J [Print Edition]. 2005 Aug 24.
   Google Scholar
• Institute for Alternative Futures. Evolving payments for improved care. Fore-sight Seminar Meeting, December 16, 2003, Washington, DC. www.altfutures.com/ foresight/Evolving%20Payments%20for%20Improved%20Care.pdf (accessed 2007 Jul 5).
   Google Scholar
• Palsson G, Rabinow P. Iceland: The case of the National Human Genome Pro-ject. Anthropology Today. 1999; 15(5):14–18.
   PubMedGoogle Scholar